Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Active Psoriatic Arthritis (BE COMPLETE)
NCT03896581Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Bimekizumab dosage regimen with Placebo (2 arms). Primary endpoint: American College of Rheumatology 50 Response at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03896581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896581.